Karuna Therapeutics, Inc. (KRTX) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は Boston, MA, アメリカ. 現CEOは William Meury.
KRTX を有する IPO日 2019-06-28, 339 名の正社員, に上場 NASDAQ Global Market, 時価総額 $12.6B.
Karuna Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative medicines for psychiatric and neurological disorders. The company's lead product candidate, KarXT, is an oral muscarinic receptor modulator currently in Phase III clinical trials for treating acute psychosis in schizophrenia patients, as well as negative and cognitive symptoms associated with schizophrenia, psychosis, and dementia-related psychosis. Karuna has established strategic partnerships with major pharmaceutical and research organizations, including Eli Lilly and Company, Zai Lab, PureTech Health, Charles River Laboratories, and PsychoGenics, Inc. Based in Boston, Massachusetts, the company was incorporated in 2009 and rebranded as Karuna Therapeutics in 2019 to reflect its expanded therapeutic focus.
